US 9909124
Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile
granted A61KA61K31/155A61K31/713
Quick answer
US patent 9909124 (Compounds and methods for modulating apolipoprotein C-III expression for improving a diabetic profile) held by Ionis Pharmaceuticals, Inc. expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Tue Mar 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61K, A61K31/155, A61K31/713, A61P, A61P3/10